COSTEM 2022 | The role of haploidentical transplantation in myelofibrosis
Nico Gagelmann
• 28 Oct 2022
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares his perspectives on the use of haploidentical transplantation in myelofibrosis (MF), explaining that haploidentical transplantation with cyclophosphamide does not prevent post-transplant relapse in patients with MF, and instead advocates for T cell depletion regimens such as busulfan, fludarabine and anti-thymocyte globulin (ATG). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
